Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2023-04-27 Earnings Release
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Earnings Release 2023
Earnings Release Classification · 99% confidence The document text explicitly details 'Q1 2023 results', provides a summary of financial performance including Total Revenue, Product Sales, and EPS figures for the first quarter, and reiterates guidance for FY 2023. This structure—quarterly financial highlights, CEO commentary, and forward guidance—is characteristic of an Earnings Release (ER). It is not a full Annual Report (10-K) or a comprehensive Interim/Quarterly Report (IR) which typically contains full, detailed financial statements, but rather the initial announcement of the results. Q1 2023
2023-04-27 English
DIRECTOR DECLARATION
Board/Management Information Classification · 100% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer submitted to the SEC. The content focuses on a director declaration announcing the appointment of a company executive as an independent director of another company. There are no financial statements, earnings data, or detailed management discussion. The document is short (2733 characters) and primarily serves as an announcement of a board/management change. It references Listing Rule 9.6.14 R (2), which relates to director appointments. Therefore, the document fits best under the category of Board/Management Information (MANG).
2023-04-26 English
Director Declaration
Board/Management Information Classification · 99% confidence The document is a formal announcement disseminated via RNS (Regulatory News Service), indicated by the 'RNS Number' and the closing boilerplate text referencing RNS and the London Stock Exchange. The core content announces a change in the board structure: the appointment of the Chief Financial Officer (Aradhana Sarin) as an independent director of another company (Anheuser-Busch InBev). This type of announcement, detailing personal share transactions or directorship changes for executives, aligns directly with the 'Director's Dealing' category (DIRS) or potentially 'Board/Management Information' (MANG). Since it specifically details a director's new appointment/role outside the primary company, MANG is a strong fit, but DIRS often covers executive appointments/changes related to governance roles. However, looking closely at the definitions, MANG is 'Announcement of changes in the company's board of directors or senior management.' This is a change in the external directorship of a senior manager, which is often reported under DIRS if it involves share dealings, but here it is purely a directorship announcement. Given the options, MANG (Board/Management Information) is the most appropriate fit for announcing a senior executive's new board role. The document is short and is a direct announcement, not a report itself, so RPA/RNS is not chosen over the specific content category.
2023-04-26 English
UPDATE TO ARRANGEMENTS WITH SOBI AND SANOFI
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides an update on contractual arrangements with Sobi and Sanofi related to the development and commercialization of nirsevimab. The document includes details about the transaction, financial impact, and background information on the product and partnerships. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. It is an announcement of a material business update rather than a full financial report. Given the nature of the content and the form type (6-K), this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-04-11 English
Update to arrangements with Sobi and Sanofi
Legal Proceedings Report Classification · 99% confidence The document is identified by the RNS Number header and the presence of the RNS distribution tracking information at the top and bottom. RNS stands for Regulatory News Service, which is a primary channel for official company announcements to the market, regulated by the FCA in the UK. The content details an update to contractual arrangements concerning a drug (nirsevimab) and the resulting financial impact ($0.7 billion gain recognized in 2023), which is a material corporate event announcement. Since this is a general, material corporate announcement disseminated via the RNS system and does not fit the specific definitions for 10-K, ER, IR, DIV, or DIRS, the most appropriate general regulatory filing category is RNS (Regulatory Filings). The document length (6397 chars) is substantial enough that it is the announcement itself, not just a brief notice pointing to an attachment (which would suggest RPA).
2023-04-11 English
LYNPARZA + IMFINZI MET ENDPOINT IN OVARIAN CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, which is a report of a foreign issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. It contains detailed information about clinical trial results (DUO-O Phase III trial) for ovarian cancer treatments Lynparza and Imfinzi, including trial design, endpoints, and background on the drugs and company. The document is dated April 2023 and is a current report rather than an annual or quarterly financial report. It does not contain financial statements or earnings data, nor is it an announcement of voting results, management changes, or capital structure updates. It is a regulatory filing providing material information about clinical trial outcomes relevant to investors. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (13,378 characters) and content confirm it is a substantive report rather than a brief announcement or certification.
2023-04-05 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.